Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy

OBJECTIVE: To analyse the survival outcomes of women with ovarian carcinosarcoma according to platinum or doxorubicin based adjuvant chemotherapy protocols. STUDY DESIGN: This retrospective study was performed at Etlik Zubeyde Hanim and Zekai Tahir Burak Women’s Health Education and Research Hospitals, which are tertiary centers in Turkey. A total of 31 women with ovarian carcinosarcoma between January 1999 and January 2013 were evaluated retrospectively. RESULTS: The mean age of patients was 53.84±10.13. Most of the patients were diagnosed with stage IIIC ovarian carcinosarcoma (n=21, 67.7%). Maximal debulking and optimal debulking was performed to 23 (74.2%) and 8 (25.8%) patients, respectively. Disease free survival was significantly shorter in stage IIIC patients when compared to stage IIIB patients (p=0.048). Disease free survival for one and three years according to the treatment protocol (platinum or doxorubicin based) was not significantly different (p=0.574). Additionally, three and five years overall survival was not significantly different (p=0.891) between the platinum and doxorubicin based chemotherapy protocols. DISCUSSION: We did not find a significant difference in terms of disease free survival and overall survival between platinum and doxorubicin based adjuvant chemotherapy protocols in women with ovarian carcinosarcoma.